PARIS, Oct. 11, 2022 /PRNewswire/ Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform
Enterome to Present at Upcoming Conferences
News provided by
Share this article
PARIS, April 7, 2021 /PRNewswire/
ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that Pierre Bélichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences:
European Biotech Investor Days: April 7-8
Jefferies Microbiome-based therapeutics Summit: April 22
Jefferies Virtual Healthcare Conference: June 1-3
Enterome s CBO, Anne Dagallier, will participate and take part in 1-on-1 meetings with potential business partners at the following conferences:
Enterome strengthens its leadership team with the appointment of Anne Dagallier as Chief Business Officer
PARIS, March 10, 2021 /PRNewswire/
ENTEROME SA, a clinical stage biopharmaceutical company developing novel therapeutics based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, is pleased to announce the appointment of Anne Dagallier, PhD, as Chief Business Officer (CBO).
Dr Dagallier brings over 22 years of experience in global business and drug development. She joins Enterome after 19 years at Sanofi where she held several scientific and senior business development positions. Most recently, she was Head of Consumer Health Care Alliances and In-Licenses at Sanofi Global Alliances Management, where she was responsible for managing strategic alliances and in licensing deals to support Sanofi s R&D pipeline.
Enterome strengthens its leadership team with the appointment of Anne Dagallier as Chief Business Officer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.